Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah(Sarah Cannon), Brendan P. Eckelman(Ambrx (United States)), Vasily Andrianov(Ambrx (United States)), James Kalabus(Ambrx (United States)), Breelyn A. Wilky(University of Colorado Cancer Center), Brianne O’Neill(Ambrx (United States)), William Crago(Ambrx (United States)), David Berz(Los Angeles Clinical Trials), Carson Veldstra(Ambrx (United States)), Katelyn M. Willis(Ambrx (United States)), Emily Rowell(Ambrx (United States)), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Monica Holcomb(Ambrx (United States)), Sant P. Chawla(Sarcoma Oncology Center), Analeah B. Heidt(Ambrx (United States)), Anthony P. Conley(The University of Texas MD Anderson Cancer Center), Abrahim Hussain(Ambrx (United States)), Lane Senne(Ambrx (United States)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 40
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
|EMBO Reports|2006|815